<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOVAZAÂ - omega-3-acid ethyl estersÂ capsule, liquid filledÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LOVAZA safely and effectively. See full prescribing information for LOVAZA.

LOVAZAÂ® (omega-3-acid ethyl esters) Capsules
Initial U.S. Approval: 2004 </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LOVAZA is a combination of ethyl esters of omega 3 fatty acids, 
principally EPA and DHA, indicated as an adjunct to diet to reduce triglyceride 
(TG) levels in adult patients with severe (â‰¥500 mg/dL) <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. 
(<a href="#S1">1</a>)<br><br> </p>
<p class="Highlighta">Limitations of Use: The effect of LOVAZA on cardiovascular mortality and 
morbidity in patients with elevated triglycerides has not been determined. 
(<a href="#S1">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>The daily dose of LOVAZA is 4 grams per day taken as a single 4-gram dose (4 
capsules) or as two 2-gram doses (2 capsules given twice daily). (<a href="#S2">2</a>)</li>
<li>Patients should be advised to swallow LOVAZA capsules whole. Do not break 
open, crush, dissolve or chew LOVAZA. (<a href="#S2">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1-gram transparent soft-gelatin capsules. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">LOVAZA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> 
(e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) to LOVAZA or any of its components. (<a href="#S4">4</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, monitor ALT and AST levels periodically 
during therapy. (<a href="#S5">5.1</a>)</li>
<li>LOVAZA may increase levels of LDL. Monitor LDL levels periodically during 
therapy. (<a href="#S5">5.1</a>)</li>
<li>Use with caution in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fish and/or 
shellfish. (<a href="#S5">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence &gt;3% and greater 
than placebo) wereÂ  <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>. (<a href="#S6">6</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact 
GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <a href="http://%0A%09%09%09%09%09%09%09#invalid_link%0A%09%09%09%09%09%09">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Omega-3-acids may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. Patients taking LOVAZA 
and an anticoagulant or other drug affecting coagulation should be monitored 
periodically. (<a href="#S7">7.1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Use during pregnancy only if the potential benefit justifies the 
potential risk to the fetus. (<a href="#S8">8.1</a>)</li>
<li>Pediatric Use: The safety and effectiveness in pediatric patients have not 
been established. (<a href="#S8">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Monitoring:  Laboratory Tests</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4188027" conceptname="Food allergy">Fish Allergy</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Anticoagulants or Other Drugs Affecting Coagulation</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Other Clinical Experience</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for Patients</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 FDA-Approved Patient Labeling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LOVAZA<span class="Sup">Â®</span> (omega-3-acid ethyl esters) is 
indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult 
patients with severe (â‰¥500 mg/dL) <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>.</p>
<p><span class="Bold">Usage Considerations:</span> Patients should be placed on an 
appropriate lipid-lowering diet before receiving LOVAZA and should continue this 
diet during treatment with LOVAZA.</p>
<p>Laboratory studies should be done to ascertain that the lipid levels are 
consistently abnormal before instituting LOVAZA therapy. Every attempt should be 
made to control serum lipids with appropriate diet, exercise, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in 
obese patients, and control of any medical problems such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus 
and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> that are contributing to the lipid abnormalities. Medications 
known to exacerbate <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (such as betaÂ blockers, thiazides, 
estrogens) should be discontinued or changed if possible prior to consideration 
of triglyceride-lowering drug therapy.</p>
<p><span class="Bold">Limitations of Use:</span> The effect of LOVAZA on 
cardiovascular mortality and morbidity in patients with elevated triglycerides 
has not been determined.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<ul>
<li>Assess triglyceride levels carefully before initiating therapy. Identify 
other causes (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, or medications) of high 
triglyceride levels and manage as appropriate. <span class="Italics">[</span><a href="#S1">see 
Indications and Usage (1)</a><span class="Italics">].</span>
</li>
<li>Patients should be placed on an appropriate lipid-lowering diet before 
receiving LOVAZA, and should continue this diet during treatment with LOVAZA. In 
clinical studies, LOVAZA was administered with meals.</li>
</ul>
<p class="First">The daily dose of LOVAZA is 4 grams per day. The daily dose may 
be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules 
given twice daily). </p>
<p>Patients should be advised to swallow LOVAZA capsules whole. Do not break 
open, crush, dissolve or chew LOVAZA.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 
1-gram transparent soft-gelatin capsules filled with light-yellow oil and 
bearing the designation LOVAZA.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LOVAZA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> 
(e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) to LOVAZA or any of its components.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Monitoring:  Laboratory Tests</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> 
(ALT) and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) levels should be monitored 
periodically during therapy with LOVAZA. In some patients, increases in ALT 
levels without a concurrent increase in AST levels were observed.</p>
<p>In some patients, LOVAZA increases LDL-C levels. LDL-C levels should be 
monitored periodically during therapy with LOVAZA. </p>
<p>Laboratory studies should be performed periodically to measure the patientâ€™s 
TG levels during therapy with LOVAZA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4188027" conceptname="Food allergy">Fish Allergy</span></h2>
<p class="First">LOVAZA contains ethyl esters of omega-3 fatty acids (EPA and DHA) 
obtained from the oil of several fish sources. It is not known whether patients 
with allergies to fish and/or shellfish, are at increased risk of an allergic 
reaction to LOVAZA. LOVAZA should be used with caution in patients with known 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fish and/or shellfish.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying 
conditions, adverse reaction rates observed in the clinical trials of a drug 
cannot be directly compared to rates in the clinical trials of another drug and 
may not reflect the rates observed in practice.</p>
<p>Adverse reactions reported in at least 3% and at a greater rate than placebo 
for patients treated with LOVAZA based on pooled data across 23 clinical studies 
are listed in Table 1.</p>
<a href="http://"></a><a name="idab27692-bef5-451f-89ac-cbe7e20ea0bd"></a><table border="1" width="441">
<caption><span>Table 1. Adverse Reactions Occurring at Incidence â‰¥3% and Greater than 
Placebo in Clinical Studies of LOVAZA</span></caption>
<col width="42%">
<col width="14%">
<col width="14%">
<col width="12%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">BODY SYSTEM</span></p>
<span class="Bold">Adverse 
Reaction*</span>
</td>
<td>
<p class="First"><span class="Bold">LOVAZA</span></p>
<span class="Bold">(N</span>Â <span class="Bold">=</span>Â <span class="Bold">655)</span>
</td>
<td>
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(N</span>Â <span class="Bold">=</span>Â <span class="Bold">370)</span>
</td>
</tr>
<tr>
<td><span class="Bold">n</span></td>
<td><span class="Bold">%</span></td>
<td><span class="Bold">n</span></td>
<td><span class="Bold">%</span></td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">Eructation</span></td>
<td>29</td>
<td>4</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td>22</td>
<td>3</td>
<td>6</td>
<td>2</td>
</tr>
<tr class="Last">
<td>Â Â <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td>27</td>
<td>4</td>
<td>1</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>Â Â Studies included subjects with HTG and severe 
HTG.<br><br></p>
<p>Additional adverse reactions from clinical studies are listed below:</p>
<p><span class="Italics">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, gastrointestinal 
disorder and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">Metabolic and Nutritional Disorders:</span> Increased ALT 
and increased AST.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, 
the events described below have been identified during post-approval use of 
LOVAZA. Because these events are reported voluntarily from a population of 
unknown size, it is not possible to reliably estimate their frequency or to 
always establish a causal relationship to drug exposure.</p>
<p>The following events have been reported: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, hemorrhagic 
diathesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Anticoagulants or Other Drugs Affecting Coagulation</h2>
<p class="First">Some studies with omega-3-acids demonstrated prolongation of 
<span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. The prolongation of <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> reported in these studies has 
not exceeded normal limits and did not produce clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 
episodes. Clinical studies have not been done to thoroughly examine the effect 
of LOVAZA and concomitant anticoagulants. Patients receiving treatment with 
LOVAZA and an anticoagulant or other drug affecting coagulation should be 
monitored periodically (e.g., aspirin, NSAIDS, warfarin, coumarin).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled 
studies in pregnant women. It is unknown whether LOVAZA can cause fetal harm 
when administered to a pregnant woman or can affect reproductive capacity. 
LOVAZA should be used during pregnancy only if the potential benefit to the 
patient justifies the potential risk to the fetus.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Underline"><span class="Italics">Animal 
Data</span></span><p>Omega-3-acid ethyl esters have been shown to have an embryocidal 
effect in pregnant rats when given in doses resulting in exposures 7 times the 
recommended human dose of 4 grams/day based on a body surface area 
comparison.</p>
<p>In female rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day 
beginning 2 weeks prior to mating and continuing through gestation and 
lactation, no adverse effects were observed in the high dose group (5 times 
human systemic exposure following an oral dose of 4 grams/day based on body 
surface area comparison).</p>
<p>In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg/kg/day 
from gestation day 6 through 15, no adverse effects were observed (14 times 
human systemic exposure following an oral dose of 4 grams/day based on a body 
surface area comparison).</p>
<p>In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day 
from gestation day 14 through lactation day 21, no adverse effects were seen at 
2,000 mg/kg/day (5 times the human systemic exposure following an oral dose of 4 
grams/day based on a body surface area comparison). However, decreased live 
births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) 
were observed in a dose-ranging study using higher doses of 3,000 mg/kg/day (7 
times the human systemic exposure following an oral dose of 4 grams/day based on 
a body surface area comparison).</p>
<p>In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg/kg/day 
from gestation day 7 through 19, no findings were observed in the fetuses in 
groups given 375 mg/kg/day (2 times human systemic exposure following an oral 
dose of 4 grams/day based on a body surface area comparison). However, at higher 
doses, evidence of maternal toxicity was observed (4 times human systemic 
exposure following an oral dose of 4 grams/day based on a body surface area 
comparison).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether omega-3-acid ethyl esters are excreted in 
human milk. Because many drugs are excreted in human milk, caution should be 
exercised when LOVAZA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been 
established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">A limited number of patients older than 65 years were enrolled in 
the clinical studies of LOVAZA. Safety and efficacy findings in subjects older 
than 60 years did not appear to differ from those of subjects younger than 60 
years.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">LOVAZA does not have any known drug abuse or withdrawal 
effects.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated 
symptomatically, and general supportive care measures instituted, as 
required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled 
gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at 
least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. 
These are predominantly a combination of ethyl esters of eicosapentaenoic acid 
(EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 
mg).</p>
<p>The empirical formula of EPA ethyl ester is C<span class="Sub">22</span>H<span class="Sub">34</span>O<span class="Sub">2</span>, and the molecular weight of EPA 
ethyl ester is 330.51. The structural formula of EPA ethyl ester is:</p>
<p><img alt="image of formula of EPA ethyl ester" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb2141cd-6cff-470c-b776-4482afcebb41&amp;name=chemical%20structure%201.jpg"></p>
<p>The empirical formula of DHA ethyl ester is C<span class="Sub">24</span>H<span class="Sub">36</span>O<span class="Sub">2</span>, and the molecular weight of DHA 
ethyl ester is 356.55. The structural formula of DHA ethyl ester is:</p>
<p><img alt="image of formula of DHA ethyl ester" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb2141cd-6cff-470c-b776-4482afcebb41&amp;name=chemical%20structure%202.jpg"></p>
<p>LOVAZA capsules also contain the following inactive ingredients: 4 mg 
Î±-tocopherol (in a carrier of soybean oil), and gelatin, glycerol, and purified 
water (components of the capsule shell).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of LOVAZA is not completely understood. 
Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol 
acyltransferase, increased mitochondrial and peroxisomal Î²-oxidation in the 
liver, decreased lipogenesis in the liver, and increased plasma lipoprotein 
lipase activity. LOVAZA may reduce the synthesis of triglycerides in the liver 
because EPA and DHA are poor substrates for the enzymes responsible for TG 
synthesis, and EPA and DHA inhibit esterification of other fatty acids.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In healthy volunteers and in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, 
EPA and DHA were absorbed when administered as ethyl esters orally. 
Omega-3-acids administered as ethyl esters (LOVAZA) induced significant, 
dose-dependent increases in serum phospholipid EPA content, though increases in 
DHA content were less marked and not dose-dependent when administered as ethyl 
esters. </p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics"><span class="Underline">Specific 
Populations</span></span><a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Age</span><p>Uptake of EPA and DHA into serum phospholipids in subjects 
treated with LOVAZA was independent of age (&lt;49 years versus <span class="Underline">&gt;</span>49 
years).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Gender</span><p>Females tended to have more uptake of EPA into serum 
phospholipids than males. The clinical significance of this is unknown.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Pediatric</span><p>Pharmacokinetics of LOVAZA in pediatric patients have not been 
established <span class="Italics">[</span><a href="#S12">see Use in Specific Populations 
(8.4)</a><span class="Italics">]</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Renal or Hepatic 
Impairment</span><p>LOVAZA has not been studied in patients with renal or hepatic 
impairment.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics"><span class="Underline">Drug-Drug 
Interactions</span></span><a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Simvastatin</span><p>In a 14-day study of 24 healthy adult subjects, daily 
co-administration of simvastatin 80 mg with LOVAZA 4 grams did not affect the 
extent (AUC) or rate (C<span class="Sub">max</span>) of exposure to simvastatin or 
the major active metabolite, beta-hydroxy simvastatin at steady state.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Atorvastatin</span><p>In a 14-day study of 50 healthy adult subjects, daily 
co-administration of atorvastatin 80 mg with LOVAZA 4 grams did not affect AUC 
or C<span class="Sub">max</span> of exposure to atorvastatin, 
2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="Italics">Rosuvastatin</span><p>In a 14-day study of 48 healthy adult subjects, daily 
co-administration of rosuvastatin 40 mg with LOVAZA 4 grams did not affect AUC 
or C<span class="Sub">max</span> of exposure to rosuvastatin at steady state.</p>
<p><span class="Italics">In vitro</span> studies using human liver microsomes 
indicated that clinically significant cytochrome P450 mediated inhibition by 
EPA/DHA combinations are not expected in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a rat carcinogenicity study with oral gavage doses of 100, 
600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl esters for 
101 weeks and females for 89 weeks without an increased incidence of tumors (up 
to 5 times human systemic exposures following an oral dose of 4 grams/day based 
on a body surface area comparison). Standard lifetime carcinogenicity bioassays 
were not conducted in mice.</p>
<p>Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without 
metabolic activation in the bacterial mutagenesis (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia 
coli</span> or in the chromosomal aberration assay in Chinese hamster V79 lung 
cells or human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Omega-3-acid ethyl esters were negative in the in 
vivo mouse micronucleus assay.</p>
<p>In a rat fertility study with oral gavage doses of 100, 600, and 2,000 
mg/kg/day, males were treated for 10 weeks prior to mating and females were 
treated for 2 weeks prior to and throughout mating, gestation, and lactation. No 
adverse effect on fertility was observed at 2,000 mg/kg/day (5 times human 
systemic exposure following an oral dose of 4 grams/day based on a body surface 
area comparison).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2>14.1 Severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">The effects of LOVAZA 4 grams per day were assessed in 2 
randomized, placebo-controlled, double-blind, parallel-group studies of 84 adult 
patients (42 on LOVAZA, 42 on placebo) with very high triglyceride levels. 
Patients whose baseline triglyceride levels were between 500 and 2,000 mg/dL 
were enrolled in these 2 studies of 6 and 16 weeks duration. The median 
triglyceride and LDL-C levels in these patients were 792 mg/dL and 100 mg/dL, 
respectively. Median HDL-C level was 23.0 mg/dL.</p>
<p>The changes in the major lipoprotein lipid parameters for the groups 
receiving LOVAZA or placebo are shown in Table 2.</p>
<a href="http://"></a><a name="i1ec89c80-65f4-45bc-8fb9-2c6922ba7ca7"></a><table border="1" width="438">
<caption><span>Table 2. Median Baseline and Percent Change From Baseline in Lipid 
Parameters in Patients with Very High TG Levels (â‰¥500 mg/dL)</span></caption>
<col width="17%">
<col width="14%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Parameter</span></td>
<td>
<p class="First"><span class="Bold">LOVAZA</span></p>
<span class="Bold">N</span>Â <span class="Bold">=</span>Â <span class="Bold">42</span>
</td>
<td>
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">N</span>Â <span class="Bold">=</span>Â <span class="Bold">42</span>
</td>
<td><span class="Bold">Difference</span></td>
</tr>
<tr>
<td><span class="Bold">BL</span></td>
<td><span class="Bold">% 
Change</span></td>
<td><span class="Bold">BL</span></td>
<td><span class="Bold">% 
Change</span></td>
</tr>
<tr>
<td>TG</td>
<td>816</td>
<td>-44.9</td>
<td>788</td>
<td>+6.7</td>
<td>-51.6</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>271</td>
<td>-13.8</td>
<td>292</td>
<td>-3.6</td>
<td>-10.2</td>
</tr>
<tr>
<td>TC</td>
<td>296</td>
<td>-9.7</td>
<td>314</td>
<td>-1.7</td>
<td>-8.0</td>
</tr>
<tr>
<td>VLDL-C</td>
<td>175</td>
<td>-41.7</td>
<td>175</td>
<td>-0.9</td>
<td>-40.8</td>
</tr>
<tr>
<td>HDL-C</td>
<td>22</td>
<td>+9.1</td>
<td>24</td>
<td>0.0</td>
<td>+9.1</td>
</tr>
<tr class="Last">
<td>LDL-C</td>
<td>89</td>
<td>+44.5</td>
<td>108</td>
<td>-4.8</td>
<td>+49.3</td>
</tr>
</tbody>
</table>
<p>BLÂ =Â Baseline (mg/dL); % ChangeÂ =Â Median Percent Change from Baseline; 
DifferenceÂ =Â LOVAZA Median % Change â€“ Placebo Median % Change<br><br></p>
<p>LOVAZA 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and 
increased median HDL-C from baseline relative to placebo. Treatment with LOVAZA 
to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in 
some individuals. Patients should be monitored to ensure that the LDL-C level 
does not increase excessively.</p>
<p>The effect of LOVAZA on the risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> in patients with very high 
TG levels has not been evaluated.</p>
<p>The effect of LOVAZA on cardiovascular mortality and morbidity in patients 
with elevated TG levels has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<h2>14.2 Other Clinical Experience</h2>
<p class="First">The effects of LOVAZA 4 grams per day as add-on therapy to 
treatment with simvastatin were evaluated in a randomized, placebo-controlled, 
double-blind, parallel-group study of 254 adult patients (122 on LOVAZA and 132 
on placebo) with persistent high triglycerides (200 to 499 mg/dL) despite 
simvastatin therapy. Patients were treated with open-label simvastatin 40 mg per 
day for 8 weeks prior to randomization to control their LDL-C to no greater than 
10% above NCEP ATP III goal and remained on this dose throughout the study. 
Following 8 weeks of open-label treatment with simvastatin, patients were 
randomized to either LOVAZA 4 grams per day or placebo for an additional 8 weeks 
with simvastatin co-therapy. The median baseline triglyceride and LDL-C levels 
in these patients were 268 mg/dL and 89 mg/dL, respectively. Median baseline 
non-HDL-C and HDL-C levels were 138 mg/dL and 45 mg/dL, respectively.</p>
<p>The changes in the major lipoprotein lipid parameters for the groups 
receiving LOVAZA plus simvastatin or placebo plus simvastatin are shown in Table 
3.</p>
<a href="http://"></a><a name="icc4acd8a-128b-4821-8466-ac10fdea28d8"></a><table border="1" width="468">
<caption><span>Table 3. Response to the Addition of LOVAZA 4 grams per day to Ongoing 
Simvastatin 40Â mg per day Therapy in Patients with High Triglycerides (200 to 
499 mg/dL)</span></caption>
<col width="15%">
<col width="6%">
<col width="8%">
<col width="13%">
<col width="6%">
<col width="8%">
<col width="14%">
<col width="14%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Parameter</span></td>
<td>
<p class="First"><span class="Bold">LOVAZA + Simvastatin</span></p>
<span class="Bold">N</span>Â <span class="Bold">=</span>Â <span class="Bold">122</span>
</td>
<td>
<p class="First"><span class="Bold">Placebo + Simvastatin</span></p>
<span class="Bold">N</span>Â <span class="Bold">=</span>Â <span class="Bold">132</span>
</td>
<td><span class="Bold">Difference</span></td>
<td><span class="Bold">P-Value</span></td>
</tr>
<tr>
<td><span class="Bold">BL</span></td>
<td><span class="Bold">EOT</span></td>
<td><span class="Bold">Median % 
Change</span></td>
<td><span class="Bold">BL</span></td>
<td><span class="Bold">EOT</span></td>
<td><span class="Bold">Median % 
Change</span></td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>137</td>
<td>123</td>
<td>-9.0</td>
<td>141</td>
<td>134</td>
<td>-2.2</td>
<td>-6.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TG</td>
<td>268</td>
<td>182</td>
<td>-29.5</td>
<td>271</td>
<td>260</td>
<td>-6.3</td>
<td>-23.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TC</td>
<td>184</td>
<td>172</td>
<td>-4.8</td>
<td>184</td>
<td>178</td>
<td>-1.7</td>
<td>-3.1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VLDL-C</td>
<td>52</td>
<td>37</td>
<td>-27.5</td>
<td>52</td>
<td>49</td>
<td>-7.2</td>
<td>-20.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Apo-B</td>
<td>86</td>
<td>80</td>
<td>-4.2</td>
<td>87</td>
<td>85</td>
<td>-1.9</td>
<td>-2.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>HDL-C</td>
<td>46</td>
<td>48</td>
<td>+3.4</td>
<td>43</td>
<td>44</td>
<td>-1.2</td>
<td>+4.6</td>
<td>&lt;0.05</td>
</tr>
<tr class="Last">
<td>LDL-C</td>
<td>91</td>
<td>88</td>
<td>+0.7</td>
<td>88</td>
<td>85</td>
<td>-2.8</td>
<td>+3.5</td>
<td>=0.05</td>
</tr>
</tbody>
</table>
<p>BL = Baseline (mg/dL); EOT = End of Treatment (mg/dL); Median % Change = 
Median Percent Change from Baseline; Difference = LOVAZA Median % Change â€“ 
Placebo Median % Change<br><br></p>
<p>LOVAZA 4 grams per day significantly reduced non-HDL-C, TG, TC, VLDL-C, and 
Apo-B levels and increased HDL-C and LDL-C from baseline relative to 
placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 
1-gram transparent soft-gelatin capsules filled with light-yellow oil and 
bearing the designation LOVAZA.</p>
<a name="if1cf89c5-9dd9-4b8f-8d6b-452e7d39b8e2"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5816-2<br>
</td>
</tr>
<tr>
<td>Bottles of 60<br>
</td>
<td>NDC 54868-5816-0<br>
</td>
</tr>
<tr>
<td>Bottles of 90<br>
</td>
<td>NDC 54868-5816-3<br>
</td>
</tr>
<tr>
<td>Bottles of 120<br>
</td>
<td>NDC 54868-5816-1<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 360<br>
</td>
<td>NDC 54868-5816-4<br>
</td>
</tr>
</tbody></table>
<p><br><br></p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see 
USP Controlled Room Temperature]. Do not freeze. Keep out of reach of 
children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling 
(</span><a href="#S17">17.2</a><span class="Italics">).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<ul>
<li>LOVAZA should be used with caution in patients with known sensitivity or 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to fish and/or shellfish <span class="Italics">[</span><a href="#S5">see Warnings and 
Precautions (5.3)</a><span class="Italics">]</span>.</li>
<li>Patients should be advised that use of lipid-regulating agents does not 
reduce the importance of adhering to diet <span class="Italics">[</span><a href="#S2">see Dosage and 
Administration (2)</a><span class="Italics">]</span>.</li>
<li>Patients should be advised not to alter LOVAZA capsules in any way and to 
ingest intact capsules only <span class="Italics">[</span><a href="#S2">see Dosage and Administration 
(2)</a><span class="Italics">]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 FDA-Approved Patient Labeling</h2>
<p class="First">Patient labeling is provided as a tear-off leaflet at the end of 
this full prescribing information.<br><br><br><br></p>
<p>Manufactured for GlaxoSmithKline by:<br>Catalent Pharma Solutions<br>2725 Scherer Drive<br>St. Petersburg, FL 33716-1016<br><br></p>
<p>Accucaps Industries Limited<br>2125 Ambassador Drive<br>Windsor, Ontario, Canada N9B 3R5<br><br></p>
<p>Banner Pharmaceuticals Inc.<br>4125 Premier Drive<br>High Point, NC 27265<br><br></p>
<p>Distributed by:<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709<br><br></p>
<p>LOVAZA is a registered trademark of the GlaxoSmithKline group of 
companies.<br><br></p>
<p>Â©2010 GlaxoSmithKline. All rights reserved.<br>December 2010<br>LVZ:6PI</p>
<br><p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br></p>
<p><br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<p class="First">PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</p>
<p>_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ __ _ _ _ _ _ _ _</p>
<a href="http://"></a><a href="http://"></a><p><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">LOVAZA<span class="Sup">Â®</span> (lÅ?-vÄ?-zÄƒ)</span></p>
<p><span class="Bold">(omega-3-acid ethyl esters) Capsules</span><br><br></p>
<p>Read the Patient Information that comes with LOVAZA before you start taking 
it, and each time you get a refill. There may be new information. This leaflet 
does not take the place of talking with your doctor about your condition or 
treatment.<br><br></p>
<p><span class="Bold">What is LOVAZA?</span></p>
<p>LOVAZA is a prescription medicine, called a lipid-regulating medicine, for 
adults. LOVAZA is made of omega-3 fatty acids from oils of fish, such as salmon 
and mackerel. Omega-3 fatty acids are substances that your body needs but cannot 
produce itself.<br></p>
<p>LOVAZA is used along with a low-fat and low-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> diet to lower very 
high triglycerides (fats) in your blood. Before taking LOVAZA, talk to your 
healthcare provider about how you can lower high blood fats by:</p>
<ul>
<li>losing weight, if you are overweight</li>
<li>increasing physical exercise</li>
<li>lowering alcohol use</li>
<li>treating diseases such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and low thyroid (<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>)</li>
<li>adjusting the dose or changing other medicines that raise triglyceride 
levels such as certain blood pressure medicines and estrogens</li>
</ul>
<p><br>Treatment with LOVAZA has not been shown to prevent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> or 
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</p>
<p>LOVAZA has not been studied in children under the age of 18 
years.<br><br></p>
<p><span class="Bold">Who should not take LOVAZA?</span></p>
<p>Do not take LOVAZA if you:</p>
<ul><li>
<span class="Bold">are allergic to LOVAZA or any of its ingredients.</span> 
See the end of this leaflet for a complete list of ingredients in 
LOVAZA.</li></ul>
<p><br><br><span class="Bold">What should I tell my doctor before taking 
LOVAZA?</span></p>
<p><span class="Bold">Tell your doctor about all of your medical conditions, 
including if you:</span></p>
<ul>
<li>drink more than 2 glasses of alcohol daily.</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
<li>have a thyroid problem called <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</li>
<li>have a liver problem.</li>
<li>have a pancreas problem.</li>
<li>are allergic to fish and/or shellfish. LOVAZA may not be right for you.</li>
<li>are pregnant, or planning to become pregnant. It is not known if LOVAZA can 
harm your unborn baby.</li>
<li>are breastfeeding. It is not known if LOVAZA passes into your milk and if it 
can harm your baby.</li>
</ul>
<p><br><br>Tell your doctor about all the medicines you take, including 
prescription and non-prescription medicine, vitamins, and herbal supplements. 
LOVAZA and certain other medicines can interact. Especially tell your doctor if 
you take medicines that affect clotting such as anticoagulants or blood 
thinners. Examples of these medicines include aspirin, nonsteroidal 
anti-inflammatory agents (NSAIDS), warfarin, coumarin, and clopidogrel 
(PLAVIX<span class="Sup">Â®</span>).</p>
<p>Know all the medicines you take. Keep a list of them with you to show your 
doctor and pharmacist.<br><br></p>
<p><span class="Bold">How should I take LOVAZA?</span></p>
<ul>
<li>Take LOVAZA exactly as prescribed. Do not change your dose or stop LOVAZA 
without talking to your doctor.</li>
<li>The usual dose of LOVAZA is 4 capsules:
<ul>
<li>Take all 4 capsules at the same time, or</li>
<li>Take 2 capsules two times a day</li>
</ul>
</li>
<li>Take LOVAZA at the same time or times each day.</li>
<li>Take LOVAZA with or without food. You may find it easier to take LOVAZA with 
food.</li>
<li>Do not take more than 4 capsules a day. Taking more than 4 capsules per day 
may increase the chance of side effects.</li>
<li>Take LOVAZA capsules whole. Do not break, crush, dissolve, or chew LOVAZA 
capsules before swallowing. If you cannot swallow LOVAZA capsules whole, tell 
your doctor. You may need a different medicine.</li>
<li>Your doctor should start you on a low-fat and low-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> diet before 
giving you LOVAZA. Stay on this low-fat and low-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> diet while taking 
LOVAZA.</li>
<li>Your doctor should do blood tests to check your triglyceride and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
levels during treatment with LOVAZA.</li>
<li>If you have liver disease, your doctor should do blood tests to check your 
liver function during treatment with LOVAZA.</li>
<li>If you miss a dose of LOVAZA, <span class="Underline">take it as soon as you 
remember. However, if you miss one day of LOVAZA, do not double your dose when 
you next take it.</span>
</li>
<li>If you take too much LOVAZA or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or Poison Control 
Center right away.</li>
</ul>
<p><br><br><span class="Bold">What are the possible side effects of LOVAZA?</span></p>
<p>The most common side effects with LOVAZA are burping, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, and a 
change in your sense of taste.</p>
<p>LOVAZA may affect certain blood tests. It may change:</p>
<ul>
<li>one of the tests to check liver function (ALT)</li>
<li>one of the tests to measure <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels (LDL-C)</li>
</ul>
<p><br><br>Talk to your doctor if you have side effects that bother you or that 
will not go away. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>These are not all the side effects with LOVAZA. For more information, ask 
your doctor or pharmacist.<br><br></p>
<p><span class="Bold">How should I store LOVAZA?</span></p>
<ul>
<li>Store LOVAZA at room temperature, 59Â° to 86Â° F (15Â° to 30Â° C). Do not 
freeze.</li>
<li>Do not keep medicine that is out of date or that you no longer need.</li>
<li>
<span class="Bold">Keep LOVAZA out of the reach of children.</span> Be sure 
that if you throw medicines away, it is out of the reach of children.</li>
</ul>
<p><br><br><span class="Bold">General information about LOVAZA</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in 
patient information leaflets. Do not use LOVAZA for a condition for which it was 
not prescribed. Do not give LOVAZA to other people, even if they have the same 
problem you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about LOVAZA. If you 
would like more information, talk with your doctor. You can ask your doctor or 
pharmacist for information about LOVAZA that is written for health professionals 
or go to <span class="Underline">www.LOVAZA.com</span>.</p>
<p><br><br><span class="Bold">What are the ingredients in LOVAZA?</span></p>
<p>Active Ingredient: Omega-3-acid ethyl esters</p>
<p>Inactive Ingredients: Gelatin, glycerol, purified water, alpha-tocopherol (in 
soybean oil)<br><br></p>
<p>LOVAZA is a registered trademark of the GlaxoSmithKline group of 
companies.</p>
<p>PLAVIX is a registered trademark of Sanofi-Synthelabo.<br><br></p>
<p>Manufactured for GlaxoSmithKline by:</p>
<p>Catalent Pharma Solutions</p>
<p>2725 Scherer Drive </p>
<p>St. Petersburg, FL 33716-1016<br><br></p>
<p>Accucaps Industries Limited</p>
<p>2125 Ambassador Drive</p>
<p>Windsor, Ontario, Canada N9B 3R5<br><br></p>
<p>Banner Pharmaceuticals Inc.</p>
<p>4125 Premier Drive</p>
<p>High Point, NC 27265<br><br></p>
<p>Distributed by: </p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709<br><br></p>
<p>Â©2010 GlaxoSmithKline. All rights reserved.<br><br></p>
<p>December 2010</p>
<p>LVZ:4PIL<br><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Lovaza<span class="Sup">Â®</span></span></p>
<p>(omega-3-acid ethyl esters) </p>
<p><span class="Bold">Capsules</span></p>
<p><span class="Bold">R<span class="Sub">x</span> only</span></p>
<p>Each capsule contains 1 gram omega-3-acid ethyl ester liquid concentrate 
consisting of at least 900 mg omega-3-acid ethyl esters.</p>
<p>Each capsule provides: Eicosapentaenoic acid (EPA) ethyl ester: 465 mg 
Docosahexaenoic acid (DHA) ethyl ester: 375 mg</p>
<p><span class="Bold">Usual Dosage</span>: See accompanying prescribing 
information.</p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); 
excursions permitted to 15<span class="Sup">o</span>-30<span class="Sup">o</span>C 
(59<span class="Sup">o</span>-86<span class="Sup">o</span>F) [see USP Controlled 
Room Temperature]. Do not freeze.</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fb2141cd-6cff-470c-b776-4482afcebb41&amp;name=5816.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVAZAÂ 		
					</strong><br><span class="contentTableReg">omega-3-acid ethyl esters capsule, liquid filled</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5816(NDC:0173-0783)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OMEGA-3-ACID ETHYL ESTERS</strong> (OMEGA-3-ACID ETHYL ESTERS) </td>
<td class="formItem">OMEGA-3-ACID ETHYL ESTERS</td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALPHA-TOCOPHEROL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (Light Yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">24mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LOVAZA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5816-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5816-1</td>
<td class="formItem">120  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5816-2</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-5816-3</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-5816-4</td>
<td class="formItem">360  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021654</td>
<td class="formItem">12/11/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>70282b0a-c6a1-4653-bf8d-89d1ce7a1d67</div>
<div>Set id: fb2141cd-6cff-470c-b776-4482afcebb41</div>
<div>Version: 2</div>
<div>Effective Time: 20090908</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
